Pillstats
Rx only · Injection, Solution · Intravenous

Cytarabine

Cytarabine

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)3041
US makers2 labelers
Packages4
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

40801201602025 Q12025 Q22025 Q32025 Q42026 Q1
50
Rx · 2026 Q1
1.4K
Units dispensed
-64%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Hospira, Inc.unknown2SUPPLYING
Meitheal Pharmaceuticals Inc.unknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jun 27, 2012
    RECALLRecall (Class II): Cytarabine Injection, 20 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hosp…

    The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution. — Recalling firm: Hospira Inc. — Nationwide, including Puerto Rico and Guam. Product was also distributed internationally to Australia, Belgium, Cana…